A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer
- Author
- KINDLER, H. L1 ; RICHARDS, D. A2 ; MCGREIVY, J11 ; BRAY, S. L12 ; HEI, Y10 ; FEIGAL, E. G10 ; LOH, E11 ; FUCHS, C. S13 ; GARBO, L. E3 ; GARON, E. B4 ; STEPHENSON, J. J5 ; ROCHA-LIMA, C. M6 ; SAFRAN, H7 ; CHAN, D8 ; KOCS, D. M9 ; GALIMI, F10
[1] Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, United States
[2] US Oncology Research, Tyler, United States
[3] US Oncology Research, Houston, United States
[4] David Geffen School of Medicine at University of California Los Angeles/Translational Oncology Research International Network, Los Angeles, United States
[5] Department of Experimental Therapeutics, Greenville Hospital System University Medical Center, Greenville, United States
[6] Department of Medicine, University of Miami/Sylvester Comprehensive Cancer Center, Miami, United States
[7] The Brown University Oncology Group, Rhode Island Hospital, Providence, United States
[8] Cancer Care Associates Medical Group, Inc., Redondo Beach, United States
[9] US Oncology Research, Round Rock, United States
[10] Global Development, Amgen Inc., Thousand Oaks, United States
[11] Global Development, Amgen Inc., South San Francisco, United States
[12] Department of Biostatistics and Epidemiology, Amgen Ltd, Cambridge, United Kingdom
[13] Department of Medical Oncology/Solid Tumor Oncology, Dana-Farber Cancer Institute, Boston, United States - Source
Annals of oncology. 2012, Vol 23, Num 11, pp 2834-2842, 9 p ; ref : 37 ref
- ISSN
- 0923-7534
- Scientific domain
- Medical oncology; Pharmacology drugs
- Publisher
- Oxford University Press, Oxford
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- AMG 479 conatumumab ganitumab gemcitabine pancreatic cancer phase 2 trial
- Keyword (fr)
- Anticancéreux Association médicamenteuse Cancer du pancréas Essai clinique phase II Gemcitabine Homme Malade Métastase Placebo Randomisation Stade avancé Conatumumab Anticorps monoclonal Antimétabolite Cancer Dérivé de la pyrimidine Fluor Composé organique Pathologie de l'appareil digestif Pathologie du pancréas Pyrimidine nucléoside Tumeur maligne
- Keyword (en)
- Antineoplastic agent Drug combination Pancreas cancer Phase II trial Gemcitabine Human Patient Metastasis Placebo Randomization Advanced stage Conatumumab Monoclonal antibody Antimetabolic Cancer Pyrimidine derivatives Fluorine Organic compounds Digestive diseases Pancreatic disease Pyrimidine nucleoside Malignant tumor
- Keyword (es)
- Anticanceroso Asociación medicamentosa Cáncer del páncreas Ensayo clínico fase II Gemcitabina Hombre Enfermo Metástasis Placebo Aleatorización Estadio avanzado Conatumumab Anticuerpo monoclonal Antimetabólito Cáncer Pirimidina derivado Fluor Compuesto orgánico Aparato digestivo patología Páncreas patología Pirimidina nucleósido Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B13 Gastroenterology. Liver. Pancreas. Abdomen / 002B13C Liver. Biliary tract. Portal circulation. Exocrine pancreas / 002B13C01 Tumors
- Discipline
- Gastroenterology. Liver. Pancreas. Abdomen Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 26554861
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1093/annonc/mds142 
https://dx.doi.org/10.1093/annonc/mds142
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mds142\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:172:\"A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"23\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"2834\";s:8:\"\u0000*\u0000epage\";s:4:\"2842\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"KINDLER\";s:10:\"\u0000*\u0000aufirst\";s:4:\"H. L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:14:\"RICHARDS, D. A\";i:1;s:11:\"MCGREIVY, J\";i:2;s:10:\"BRAY, S. L\";i:3;s:6:\"HEI, Y\";i:4;s:12:\"FEIGAL, E. G\";i:5;s:6:\"LOH, E\";i:6;s:11:\"FUCHS, C. S\";i:7;s:11:\"GARBO, L. E\";i:8;s:11:\"GARON, E. B\";i:9;s:16:\"STEPHENSON, J. J\";i:10;s:16:\"ROCHA-LIMA, C. M\";i:11;s:9:\"SAFRAN, H\";i:12;s:7:\"CHAN, D\";i:13;s:10:\"KOCS, D. M\";i:14;s:9:\"GALIMI, F\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:172:\"A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mds142\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:172:\"A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"23\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"2834\";s:8:\"\u0000*\u0000epage\";s:4:\"2842\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"KINDLER\";s:10:\"\u0000*\u0000aufirst\";s:4:\"H. L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:14:\"RICHARDS, D. A\";i:1;s:11:\"MCGREIVY, J\";i:2;s:10:\"BRAY, S. L\";i:3;s:6:\"HEI, Y\";i:4;s:12:\"FEIGAL, E. G\";i:5;s:6:\"LOH, E\";i:6;s:11:\"FUCHS, C. S\";i:7;s:11:\"GARBO, L. E\";i:8;s:11:\"GARON, E. B\";i:9;s:16:\"STEPHENSON, J. J\";i:10;s:16:\"ROCHA-LIMA, C. M\";i:11;s:9:\"SAFRAN, H\";i:12;s:7:\"CHAN, D\";i:13;s:10:\"KOCS, D. M\";i:14;s:9:\"GALIMI, F\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:172:\"A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mds142\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mds142\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:172:\"A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"23\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"2834\";s:8:\"\u0000*\u0000epage\";s:4:\"2842\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"KINDLER\";s:10:\"\u0000*\u0000aufirst\";s:4:\"H. L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:14:\"RICHARDS, D. A\";i:1;s:11:\"MCGREIVY, J\";i:2;s:10:\"BRAY, S. L\";i:3;s:6:\"HEI, Y\";i:4;s:12:\"FEIGAL, E. G\";i:5;s:6:\"LOH, E\";i:6;s:11:\"FUCHS, C. S\";i:7;s:11:\"GARBO, L. E\";i:8;s:11:\"GARON, E. B\";i:9;s:16:\"STEPHENSON, J. J\";i:10;s:16:\"ROCHA-LIMA, C. M\";i:11;s:9:\"SAFRAN, H\";i:12;s:7:\"CHAN, D\";i:13;s:10:\"KOCS, D. M\";i:14;s:9:\"GALIMI, F\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:172:\"A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mds142\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:172:\"A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"23\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"2834\";s:8:\"\u0000*\u0000epage\";s:4:\"2842\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"KINDLER\";s:10:\"\u0000*\u0000aufirst\";s:4:\"H. L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:14:\"RICHARDS, D. A\";i:1;s:11:\"MCGREIVY, J\";i:2;s:10:\"BRAY, S. L\";i:3;s:6:\"HEI, Y\";i:4;s:12:\"FEIGAL, E. G\";i:5;s:6:\"LOH, E\";i:6;s:11:\"FUCHS, C. S\";i:7;s:11:\"GARBO, L. E\";i:8;s:11:\"GARON, E. B\";i:9;s:16:\"STEPHENSON, J. J\";i:10;s:16:\"ROCHA-LIMA, C. M\";i:11;s:9:\"SAFRAN, H\";i:12;s:7:\"CHAN, D\";i:13;s:10:\"KOCS, D. M\";i:14;s:9:\"GALIMI, F\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:172:\"A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mds142\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:172:\"A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"23\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"2834\";s:8:\"\u0000*\u0000epage\";s:4:\"2842\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"KINDLER\";s:10:\"\u0000*\u0000aufirst\";s:4:\"H. L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:14:\"RICHARDS, D. A\";i:1;s:11:\"MCGREIVY, J\";i:2;s:10:\"BRAY, S. L\";i:3;s:6:\"HEI, Y\";i:4;s:12:\"FEIGAL, E. G\";i:5;s:6:\"LOH, E\";i:6;s:11:\"FUCHS, C. S\";i:7;s:11:\"GARBO, L. E\";i:8;s:11:\"GARON, E. B\";i:9;s:16:\"STEPHENSON, J. J\";i:10;s:16:\"ROCHA-LIMA, C. M\";i:11;s:9:\"SAFRAN, H\";i:12;s:7:\"CHAN, D\";i:13;s:10:\"KOCS, D. M\";i:14;s:9:\"GALIMI, F\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:172:\"A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
